Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Atomo Diagnostics Ltd. ( (AU:AT1) ) is now available.
Atomo Diagnostics Limited has secured a US$410,000 order from Lumos Diagnostics for Pascal cassettes, following Lumos’s agreement with PHASE Scientific to distribute the FebriDx test in the US. The FebriDx test, which uses Atomo’s Pascal cassette, has FDA clearance and is undergoing a CLIA waiver study. The agreement is expected to significantly boost demand for Atomo’s Pascal cassettes, with potential sales of up to US$316 million over six years, contingent on regulatory approvals and minimum order quantities.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an Australian medical device company that provides integrated rapid diagnostic test devices for the global diagnostic market. Their patented devices are designed to simplify testing procedures, enhance usability, and improve reliability for point-of-care and at-home testing applications. The company has commercialized products internationally and has supply agreements for testing applications targeting infectious diseases such as HIV, Syphilis, and viral versus bacterial differentiation, as well as early pregnancy detection.
Average Trading Volume: 1,141,460
Technical Sentiment Signal: Hold
Current Market Cap: A$14.97M
For a thorough assessment of AT1 stock, go to TipRanks’ Stock Analysis page.